Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:FLGCNASDAQ:NERVNASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.00-0.5%$2.43$1.63▼$6.15$9.36M1.21279,144 shs34,194 shsFLGCFlora Growth$0.49+2.3%$0.71$0.42▼$2.41$9.52M2.01293,940 shs336,499 shsNERVMinerva Neurosciences$1.34-3.6%$1.80$1.18▼$3.69$9.37M-0.0928,842 shs56,468 shsPALIPalisade Bio$0.71+2.2%$0.89$0.60▼$9.65$3.10M1.5756,930 shs46,793 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+1.01%-6.07%-23.28%-10.27%-65.45%FLGCFlora Growth-0.17%-20.12%-26.54%-52.55%-78.89%NERVMinerva Neurosciences-3.69%-14.19%-18.90%-40.36%-47.64%PALIPalisade Bio-5.45%+3.02%-18.62%-65.67%-88.73%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.7199 of 5 stars3.83.00.00.02.02.50.6FLGCFlora Growth3.0834 of 5 stars3.35.00.00.03.10.81.3NERVMinerva Neurosciences3.1077 of 5 stars3.05.00.04.60.00.00.0PALIPalisade Bio1.5064 of 5 stars3.52.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,150.00% UpsideFLGCFlora Growth 2.67Moderate Buy$5.00920.41% UpsideNERVMinerva Neurosciences 2.00Hold$5.00273.13% UpsidePALIPalisade Bio 3.00Buy$23.003,162.41% UpsideCurrent Analyst Ratings BreakdownLatest PALI, NERV, BCDA, and FLGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/26/2025NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.001/30/2025BCDABioCardiaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 4/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$58K161.38N/AN/A($1.11) per share-1.80FLGCFlora Growth$59.51M0.16N/AN/A$0.78 per share0.63NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/APALIPalisade Bio$250K12.40N/AN/A$18.29 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$11.57M-$3.09N/AN/AN/A-1,999.77%N/A-208.38%5/13/2025 (Estimated)FLGCFlora Growth-$57.04M-$1.32N/AN/AN/A-30.99%-268.17%-57.51%5/13/2025 (Estimated)NERVMinerva Neurosciences-$30M$0.19N/AN/AN/AN/AN/A-6.74%4/29/2025 (Estimated)PALIPalisade Bio-$12.30M-$10.92N/AN/AN/AN/A-148.51%-115.16%5/12/2025 (Estimated)Latest PALI, NERV, BCDA, and FLGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NERVMinerva Neurosciences-$1.07N/AN/AN/AN/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million3/24/2025Q4 2024FLGCFlora Growth-$0.11-$0.42-$0.31-$0.45$13.55 million$13.33 million3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/A2/27/2025Q4 2024NERVMinerva Neurosciences-$1.05-$0.56+$0.49-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A1.781.78FLGCFlora Growth0.431.020.64NERVMinerva NeurosciencesN/A6.236.23PALIPalisade BioN/A3.313.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%FLGCFlora Growth36.01%NERVMinerva Neurosciences34.56%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%FLGCFlora Growth12.99%NERVMinerva Neurosciences8.60%PALIPalisade Bio3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia404.68 million3.67 millionOptionableFLGCFlora Growth28019.44 million12.55 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionablePALIPalisade Bio104.40 million2.68 millionNot OptionablePALI, NERV, BCDA, and FLGC HeadlinesRecent News About These CompaniesPalisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108April 9 at 8:58 PM | markets.businessinsider.comPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108April 9 at 8:30 AM | globenewswire.comMaxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.comPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialMarch 17, 2025 | finance.yahoo.comPalisade Bio commences dosing in first UC patient cohort in study of PALI-2108March 14, 2025 | markets.businessinsider.comPalisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative ColitisMarch 14, 2025 | quiverquant.comPalisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108March 14, 2025 | globenewswire.comPalisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025March 12, 2025 | globenewswire.comPalisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?March 7, 2025 | zacks.comPalisade Bio Participates in Virtual Investor “What This Means” SegmentMarch 4, 2025 | globenewswire.comPalisade Bio receives cash proceeds from Canada’s SR&ED tax incentive programFebruary 20, 2025 | markets.businessinsider.comPalisade Bio Secures CAD$1.39 Million in SR&ED Funding for PALI-2108 Development EffortsFebruary 20, 2025 | quiverquant.comPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)February 20, 2025 | globenewswire.comPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comPalisade Bio presents preclinical data of PALI-2108February 10, 2025 | markets.businessinsider.comPalisade Bio Presents Positive Preclinical Data for PALI-2108 in Ulcerative Colitis at 2025 Crohn’s and Colitis CongressFebruary 10, 2025 | quiverquant.comPalisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative ColitisFebruary 10, 2025 | globenewswire.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis CongressJanuary 30, 2025 | markets.businessinsider.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis CongressJanuary 29, 2025 | globenewswire.comPALI stock plunges to 52-week low, touches $1.34January 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, NERV, BCDA, and FLGC Company DescriptionsBioCardia NASDAQ:BCDA$2.01 +0.00 (+0.20%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Flora Growth NASDAQ:FLGC$0.49 +0.01 (+2.25%) Closing price 04:00 PM EasternExtended Trading$0.48 -0.02 (-3.06%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.Minerva Neurosciences NASDAQ:NERV$1.36 -0.04 (-2.52%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Palisade Bio NASDAQ:PALI$0.70 +0.02 (+2.17%) Closing price 03:56 PM EasternExtended Trading$0.69 -0.01 (-1.56%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Alphabet a Generational Buying Opportunity at These Levels? Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder? Amazon Stock Bounces From Lows as Smart Money Steps In Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
